HOOK (HOOKIPA Pharma) Gross Margin %: 0.00% (As of Jun. 2025)


HOOK HOOKIPA Pharma Inc HOOK
49 GF Score
Price $1.15
GF Value $2.78
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is HOOKIPA Pharma Gross Margin %?

HOOKIPA Pharma HOOK 49 Gross Margin % is 0.00% as of Jun. 2025. GuruFocus rates HOOK with a GF Score™ of 49/100 and a GF Value™ of $2.78 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 738 Biotechnology companies, HOOKIPA Pharma ranks worse than 135501.22% on this metric.

Gross Margin % is calculated as gross profit divided by its revenue. HOOKIPA Pharma's Gross Profit for the three months ended in Jun. 2025 was $6.80 Mil. HOOKIPA Pharma's Revenue for the three months ended in Jun. 2025 was $6.80 Mil. Therefore, HOOKIPA Pharma's Gross Margin % for the quarter that ended in Jun. 2025 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for HOOKIPA Pharma's Gross Margin % or its related term are showing as below:


HOOK's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.94
* Ranked among companies with meaningful Gross Margin % only.

HOOKIPA Pharma had a gross margin of N/A% for the quarter that ended in Jun. 2025 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for HOOKIPA Pharma was 0.00% per year.


HOOKIPA Pharma  (OTCPK:HOOK) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

HOOKIPA Pharma had a gross margin of N/A% for the quarter that ended in Jun. 2025 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


HOOKIPA Pharma Gross Margin % Related Terms


HOOKIPA Pharma Gross Margin % Historical Data

* Premium members only.

The historical data trend for HOOKIPA Pharma's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HOOKIPA Pharma Gross Margin % Chart

HOOKIPA Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

HOOKIPA Pharma Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HOOK vs LNAI, ZEOX, GDTC: Gross Margin % Comparison

For the Biotechnology subindustry, HOOKIPA Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HOOKIPA Pharma Gross Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's Gross Margin % distribution charts can be found below:

* The bar in red indicates where HOOKIPA Pharma's Gross Margin % falls into.


HOOK
49GF Score
HOOKIPA Pharma Inc HOOK
Gross Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HOOKIPA Pharma Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

HOOKIPA Pharma's Gross Margin for the fiscal year that ended in Dec. 2024 is calculated as

Gross Margin % (A: Dec. 2024 )=Gross Profit (A: Dec. 2024 ) / Revenue (A: Dec. 2024 )
=43.9 / 43.946
=(Revenue - Cost of Goods Sold) / Revenue
=(43.946 - 0) / 43.946
=N/A %

HOOKIPA Pharma's Gross Margin for the quarter that ended in Jun. 2025 is calculated as


Gross Margin % (Q: Jun. 2025 )=Gross Profit (Q: Jun. 2025 ) / Revenue (Q: Jun. 2025 )
=6.8 / 6.795
=(Revenue - Cost of Goods Sold) / Revenue
=(6.795 - 0) / 6.795
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Frequently Asked Questions Learn more about Gross Margin % →
What does a Gross Margin % of 0.00% mean?
HOOKIPA Pharma (HOOK) has a Gross Margin % of 0.00% as of Jun. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on HOOKIPA Pharma and its competitors. According to the industry distribution chart, HOOKIPA Pharma ranks #999999 out of 738 companies in the Biotechnology industry.
Is HOOKIPA Pharma's Gross Margin % too high?
HOOKIPA Pharma's current Gross Margin % is 0.00%. Based on the distribution chart, HOOKIPA Pharma ranks #999999 out of 738 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, HOOKIPA Pharma has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's Gross Margin % compare to LNAI and ZEOX?
According to the Biotechnology industry distribution chart, HOOKIPA Pharma ranks #999999 out of 738 companies for Gross Margin %. This places HOOKIPA Pharma in the lower half of its industry. The industry median Gross Margin % is 60.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on HOOKIPA Pharma and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HOOKIPA Pharma's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
Based on GuruFocus' analysis, HOOKIPA Pharma (HOOK) is currently considered Possible Value Trap. The stock's GF Value™ is $2.78, compared to a current price of $1.15 — trading 58.6% below its estimated fair value. The current Gross Margin % is 0.00%. HOOKIPA Pharma's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current Gross Margin % is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HOOKIPA Pharma (HOOK) Overvalued in 2026?

Based on GuruFocus' analysis, HOOKIPA Pharma stock appears to be undervalued. The current stock price of $1.15 is trading 58.6% below its estimated GF Value™ of $2.78. GuruFocus considers HOOKIPA Pharma to be Possible Value Trap.

Key valuation signals for HOOK:

  • Gross Margin %: 0.00%
  • GF Value™: $2.78 vs. price of $1.15 (58.6% below fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the HOOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


HOOKIPA Pharma Business Description

Address 350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY, USA, 10118
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
49GF Score

Get the complete analysis for HOOK

Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.15
Price
$2.78
GF Value